CUE
Cue Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.44
−0.83%Year over year
Reported trailing growth
- Revenue
- +354.4%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- -77.1%
- Operating cash flow
- -77.8%
Forward estimates
Based on analyst estimates
- Revenue
- -91.9%
- EBITDA
- +83.2%
- EPS
- +90.5%
Three-year CAGR
- Revenue
- +180.5%
- EBITDA
- +40.7%
- EBIT
- +36.1%
- Net income
- +34.6%
- EPS
- +61.1%
- Free cash flow
- +39.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026